Navigating the Evolving Landscape of HER2-Positive Early-Stage Breast Cancer: Considerations for Managed Care

Program Description

Evidence has shown that HER2-targeted therapies have improved outcomes for patients with HER2-positive breast cancer. Patients with early-stage disease are at greater risk of disease recurrence and often identify risk of recurrence and financial burden of treatment as significant concerns. While some patients with early-stage breast cancer do not need adjuvant therapy, the treatment options have expanded, and managed care pharmacists are a critical part of appropriate treatment selection. Research is ongoing to identify the potential role and best practices for utilization of HER2-targeted therapies in early-stage breast cancer. Managed care pharmacists must be informed about emerging treatment options to develop policies that facilitate access to safe and effective treatments to improve long-term outcomes for patients with HER2-positive breast cancer. This article will recap existing guideline recommendations for HER2-positive early-stage breast cancer as well as prepare managed care pharmacists to incorporate these new therapeutic approaches into patient management plans.

Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: December 19, 2023
Expiration date: December 19, 2024
Time to complete activity: 2.0 hours
Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the correlation between risk stratification and therapeutic choices in HER2-positive early-stage breast cancer.
• Investigate the advancements and changes in the treatment landscape of HER2-positive early-stage breast cancer.
• Analyze the operational implications of integrating new therapies into the treatment paradigm for HER2-positive early-stage breast cancer.

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-472-H01-P. The activity is available for CE credit through December 19, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Laura R. Bobolts, PharmD, BCOP

Medical Writing and Editorial Support

Shetal Desai, PharmD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green

Pharmacy Times® Editorial Staff—Aislinn Antrim

Pharmacy Times Continuing Education^™ Planning Staff—Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Former employee: GSK

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms